RxDoctor Payments Data

Seth Keller, MD

Neurology · Lumberton, NJNPI 1366557043

Payments from drug & device makers

$27,394in general payments, 2019–2025

Across 832 payments — averaging $32.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Catalyst Pharmaceuticals, Inc.$13K
  • Jazz Pharmaceuticals Inc.$1K
  • Biogen$1K
  • EMD Serono, Inc.$1K
  • AbbVie$1K
  • UCB, Inc.$915
  • plus $8K from 54 others

What the payments were for

  • Consulting fees$1,3375%
  • Speaking & faculty fees$11,10841%
  • Travel & lodging$1,1914%
  • Food & beverage$13,68150%
  • Education$780%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Catalyst Pharmaceuticals, Inc.16$12,936
Jazz Pharmaceuticals Inc.8$1,452
Biogen66$1,383
EMD Serono, Inc.120$1,294
AbbVie(2 entities)77$1,080
UCB, Inc.61$915
Pfizer55$665
SK Life Science, Inc.29$633
Lilly USA, LLC35$608
Validus Pharmaceuticals LLC11$520
Teva Pharmaceuticals USA, Inc.26$362
AstraZeneca20$354
Sunovion Pharmaceuticals Inc.24$334
Eisai Inc.24$310
W. L. Gore & Associates, Inc.10$253
Novartis20$249
Argenx US, Inc.16$239
ANI Pharmaceuticals, Inc.11$223
Neurelis, Inc.8$219
Medtronic3$183
Greenwich Biosciences, Inc.4$177
Acorda Therapeutics, Inc10$154
Adamas Pharmaceuticals, Inc.10$135
Sumitomo Pharma America, Inc.7$126
Aquestive Therapeutics, Inc.8$123
Scilex Pharmaceuticals Inc.8$123
Livanova USA, Inc.2$121
Genentech USA, Inc.8$116
Avanir Pharmaceuticals, Inc.8$110
Boston Scientific7$107
Biohaven Pharmaceutical Holding Company Ltd.7$98
Vanda Pharmaceuticals Inc.6$98
Neurocrine Biosciences, Inc.7$96
Abbott4$95
GE HealthCare6$94
Sanofi6$93
Mallinckrodt Hospital Products Inc.6$88
Johnson & Johnson(2 entities)6$85
Lundbeck LLC5$82
Avion Pharmaceuticals5$78
Axsome Therapeutics, Inc.4$71
Acadia Pharmaceuticals Inc5$70
Kyowa Kirin, Inc.5$70
Otsuka America Pharmaceutical, Inc.4$67
Merz Pharmaceuticals, LLC2$58
Mallinckrodt Enterprises LLC4$57
Aucta Pharmaceuticals, Inc.4$54
Amneal Pharmaceuticals LLC3$51
Grifols USA, LLC3$45
Arbor Pharmaceuticals, Inc.3$44
Biohaven Pharmaceuticals, Inc.3$38
Banner Life Sciences, LLC2$35
Azurity Pharmaceuticals, Inc.2$31
Collegium Pharmaceutical, Inc.2$28
Ceribell, Inc.1$26
CSL Behring1$24
Supernus Pharmaceuticals, Inc.2$23
Impel Pharmaceuticals LLC1$23
Otter Pharmaceuticals, LLC1$18
Impel Pharmaceuticals Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,394 in reported general payments places this provider in the 80th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$154,877
Medicare patients
741
Services billed
1,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab13$659,405
FinteplaFenfluramine Hcl11$213,856
VumerityDiroximel Fumarate12$105,624
FingolimodFingolimod Hcl29$101,485
EpidiolexCannabidiol (Cbd)11$85,466
FycompaPerampanel48$75,069
XcopriCenobamate27$52,110
AptiomEslicarbazepine Acetate27$44,963
GlatopaGlatiramer Acetate13$41,731
Emgality PenGalcanezumab-Gnlm26$27,424
Levetiracetam238$18,386
Lacosamide103$17,412
ValtocoDiazepam11$12,920
BotoxOnabotulinumtoxina11$11,746
NayzilamMidazolam14$10,933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$354$659,40513 claims
UCB, Inc.Fintepla, Nayzilam$915$224,78925 claims
BiogenVumerity$1,383$105,62412 claims
Eisai Inc.Fycompa$310$75,06948 claims
SK Life Science, Inc.Xcopri$633$52,11027 claims
Sunovion Pharmaceuticals Inc.Aptiom$334$44,96327 claims
Neurelis, Inc.Valtoco$219$12,92011 claims
AbbVieBotox$1,080$11,74611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 521 neurology providers in New Jersey.

Other neurology in Lumberton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →